Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals

2017-09-01
Price :
Published : Sep-2017
No. of Pages : 77

Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals

Summary

GlobalData’s “Partnerships, Licensing, Investments and M&A Deals and Trends for July 2017 in Pharmaceuticals”, report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in July 2017. The report portrays detailed comparative data on the number of deals and their value in the last six months, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData’s proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

The pharmaceutical and healthcare industry reported a decrease in the number of deals and deal values in July 2017. The industry reported 314 deals worth USD29.5 billion in July 2017, compared to 392 deals worth USD31.5 billion in June 2017. The oncology therapeutics market remained at the top in deal activity in July 2017 with 104 deals. In second place, infectious disease therapeutics market reported 60 deals. Licensing agreements in pharmaceutical and healthcare industry registered an increase in upfront payments. The segment reported USD203.7m as upfront payments in July 2017, compared to USD130m in June 2017. The number of deals in North America decreased to 203 in July 2017 from 254 in June 2017.

Scope

– Analysis of the market trends for the pharmaceutical industry in the global arena.
– Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women’s health segments.
– Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
– Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
– Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
– Analysis of partnership and licensing deals based on clinical stage of development of products.
– Summary of the pharmaceutical deals globally in the six months.
– Information on the top deals happened in the pharmaceutical industry.
– Geographies covered include – North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
– League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

– Enhance your decision making capability in a more rapid and time sensitive manner.
– Find out the major deal performing segments for investments in your industry.
– Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
– Identify companies that are aggressively looking to raise capital in the market
– Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
– Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
– Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
– Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
– Identify growth segments and opportunities in each region within the industry.
– Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Pharm-Olam International Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Pharm-Olam International Ltd (Pharm-Olam) is a contract research organization (CRO) which offers clinical research services to the pharmaceutical, biotechnology and medical device industries. The organization's service offerings include medical writing, monitoring, regulatory and ethics submissions, data management, biostatistics, pharmacovigilance, rescue studies, project management, import and export licenses, contract negotiation and administration and product registration among others. Pharm-Olam's target therapeutic areas include anti-infectives, cardiology, dermatology, endocrinology, gastroenterology, oncology, respiratory, rheumatology, and others. The company has operations across North America, Western Europe, Central and Eastern Europe, Latin America, Asia and South A......
$250

Novaliq GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Novaliq GmbH (Novaliq) is a drug delivery company that develops pharmaceutical formulations. The company develops novel ophthalmic and dermatological products, and solutions for organ preservation based on the physicochemical properties of semifluorinated alkanes. It offers NovaTears, a preservative free eye drop product for the relief of discomfort under dry eye syndrome. Novaliq also has products in pipeline for the treatment of glaucoma and other retinal diseases. The company offers its SFA technology as a delivery platform for external co-development cooperations. It licenses its SFA technology to distribution partners who completes registration studies. Novaliq is headquartered in Heidelberg, Germany. Novaliq GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Prof......
$250

Fidia farmaceutici SpA – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Fidia farmaceutici SpA (Fidia), a subsidiary of P&R S.p.A., is a healthcare products provider that specializes in research, development and manufacturing of hyaluronic acid-based products. The company develops and commercializes products for specific therapeutic areas which includes joint health care with primary emphasis on osteoarthritis; advanced wound care; and aesthetic medicine. It also offers products for other therapeutic areas such as impaired joint function; acute localized pain; herpes labialis; burns and rashes. Fidia operates along with its subsidiaries located in the US, Germany and Kazakhstan. The company works in partnership with pharmaceutical and biomedical companies to commercializes its products worldwide. Fidia is headquartered in Abano Terme, Italy. Fidi......
$250

Immunomic Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Immunomic Therapeutics Inc (ITI) is a biotechnology company that specializes in developing vaccines based on the patented lysosomal associated membrane protein or lamp technology. The company's pipeline product portfolio drugs for allergy vaccine therapy and oncology immunotherapy. It develops vaccine therapies by incorporating the genetic sequence for LAMP protein as part of the DNA vaccine. ITI's product development pipeline also focuses on the allergy product area for internal development including products for global cedar, juniper, cypress allergy, peanut allergy and flea allergy in dogs. The company's LAMP-vax technology vaccines encode the expression of a fusion protein that includes the therapeutic antigen and the LAMP targeting protein. ITI is headquartered in Rockville......
$250

Crescendo Biologics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Crescendo Biologics Ltd (Crescendo) is a biopharmaceutical company that manufactures antibody therapeutics based on a transgenic mouse platform. The company s pipeline includes humabody programs targeting oncology. It specializes in the antibody discoveries and development that include CAT, medimmune, morphosys and GSK. Crescendo develops a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The company's oncology programmes produce high value, novel therapeutics that capitalizes on advantages of the Humabody VH format. Crescendo is headquartered in Cambridge, the UK. Crescendo Biologics Ltd - Pharmaceuticals & Healthcare - Deals and Allia......
$250

Institut Curie – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Institut Curie is a cancer research foundation that operates cancer research institutes and hospitals and concentrates on the developing new treatments for cancer. The foundation carries out research in the areas of immunology, pharmachemistry, bioinformatics and systems biology, cell biology and developmental biology, genetics and carcinogenesis, cell and tissue imaging, and others. It provides care, research and training services for detecting, treating and monitoring cancer. Institut Curie offers services in anesthesia, medicine, pediatrics, surgery, tumor biology, intensive care, pain, medical imaging, and others. The foundation provides masters, PhD and postdoctoral fellowship programmes and other courses. Institut Curie is headquartered in Paris, France. Institut Curie ......
$250

Zavante Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Zavante Therapeutics Inc (Zavante), formerly SG Pharmaceuticals Inc is a developer of novel therapies for the treatment of infectious diseases. The company offers drugs for the treatment of diseases that affect patients in the hospital setting. Its lead product candidate ZOLYD, is an investigational first-in-class injectable epoxide antibiotic. Zavante's ZOLYD is being developed for the treatment of infectious diseases such as complicated urinary tract infections, acute bacterial skin and skin structure infections, and others. The company works in collaboration with private and public firms to conduct its research and development activities. Zavante is headquartered in San Diego, California, the US. Zavante Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances......
$250

Tenet Healthcare Corp (THC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Tenet Healthcare Corp (Tenet) is a health care services company that operates hospitals, diagnostic imaging centers, ambulatory surgery centers, and related health care facilities along with its subsidiaries and affiliates. It is one of the leading healthcare services companies in the US, with a comprehensive healthcare delivery network. The company serves urban and rural communities in US through general hospitals, including children's hospitals, specialty hospitals, academic medical centers and critical access hospitals. Tenet's subsidiaries provide healthcare services through several free-standing and provider-based diagnostic imaging centers, free-standing emergency department, urgent care centers and ambulatory surgery centers. It also operates private hospitals and clinics......
$250

PsiOxus Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary PsiOxus Therapeutics Ltd (PsiOxus), formerly known as Myotec Therapeutics Ltd, is a drug company that develops novel therapeutics for cancer and other clinically unmet diseases. The company's pipeline product portfolio includes an oncolytic vaccine and a dual action anabolic catabolic transforming agent. It also has an antibody armed oncolytic platform under development. PsiOxus's products find application in the treatment of various cancer diseases such as cachexia, sarcopenia, metastatic cancer, and solid tumours, among others. It holds expertise in enhancing the therapeutic potency, safety and delivery kinetics through genetic modification to produce cancer vaccines. PsiOxus is headquartered in Abingdon, the UK. PsiOxus Therapeutics Ltd - Pharmaceuticals & Healthcare - Dea......
$250

Mission Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile

Summary Mission Therapeutics Ltd (Mission) is a drug discovery company that develops small molecule drugs targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases. The company's USP30 is the DUB that localizes to the outer mitochondrial membrane. Its USP7 is a DUB with oncology links and an anti-cancer target. Mission's DUB programmes also include a number of other DUB targets in oncology such as DNA damage response and synthetic lethal mechanisms, neurodegeneration and inflammation. The company receives grants to support the discovery and preclinical development of inhibitors directed against a specific DUB. Mission is headquartered in Cambridge, the UK. Mission Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you......
$250